While discussing about the frontline role of biotechnologists in the COVID-19 research in Bangladesh, Mahmud-Al-Rafat argues about the need of a uniform government policy and recognition for the biotechnologists
WE ARE often saying that the ongoing COVID-19 pandemic has become an eye opener to us but have our eyes really opened? Are we being able to use all our available resources? Though the government is trying to accommodate all expert opinions to fight this war but still some are remain unnoticed. Government cannot fight alone in this pandemic situation, it is also our duty to support the government to make the right decisions and make them accountable for their actions.
This is the right time when we need all hands for not only logistics availability but also we need proper placement of skilled persons. An appropriate utilisation of our human resources is a must to win this war. Here comes both the necessity and negligence towards biotechnologists that remains unnoticed. Being an executive committee member of Bangladesh Association of Biotechnology Graduates, a national platform for biotechnologist, I am privileged to know many untold stories of brave and skilled biotechnologists as well as unfortunate to see how they remain the unsung heroes in this COVID-19 war.
BABG feels the urge to bring these heart touching stories of those young bloods who have sacrificed their personal and family safety in order to support the people in this grave situation. Yes, we are talking about those more than 100 biotechnologists who has served voluntarily in many COVID-19 testing laboratories since March 2020. Some of them are involved in developing laboratory set up and giving training to medical personnel about RT-PCR based test method while some others are involved in doing the test to support increasing governments capacity in COVID-19 management by following test, trace, isolate and support.
Let me share about some brave soul among those front line fighters. Young and energetic biotechnologist Kazi Porag was engaged in developing eight different COVID-19 testing facility since the beginning and now he is a COVID-19 patient himself. Having full knowledge about the life risk during this pandemic, Porag could not resist himself from his duty and responsibility. Being COVID-19 positive is not that much frustrating to him than knowing that after doing all this, still people are saying, this is not the place for biotechnologists, while standing in the lab he developed.
Another skilled biotechnologist, Md Salauddin, is moving across the country since March as a part of his job. His job is to establish RT-PCR labs and train-up people for doing this test. He has been successful to establish so many labs yet has failed to establish the fact that biotechnologists can lead molecular diagnostics.
An inspiring biotechnologist Sabiha Pia started working voluntarily in a lab developed by Salauddin. Dealing with viruses on daily basis, she had to isolate herself from her family members and stay in a small rooftop room. Her family gave her full support but still it was hard for her little boy to support his mom. However the kid is happy now to have his mother back but did Sabiha returned with happy memories? Well, she never had. Because, in this situation, after developing lab, Porag and Salauddin failed to get recognition. BABG talked with many volunteers who were working in many labs across the country. Almost all of them faced negligence and insult while supporting the government fully voluntarily to fight this war. Biotechnology volunteers jumped in this grave situation to support the government without any hesitation and they were prepared to fight COVID-19 but they were not prepared to fight the unwelcomed surroundings. None of them are part of any government support, allowance or any stimulus package even when it comes to get appointed for short period their names come last or even never.
From the beginning BABG was trying to support our government to fight this COVID-19 war by providing volunteers and experts. However, we have noticed that many of our volunteers were hindered to do their job and many of them had to discontinue though these are not by their will. Actually, we have to prepare more volunteers but before that we have to ensure their proper recognition, safety, equal opportunity with other COVID-19 fighters and a friendly environment.
Recently few recruitments and circulars of molecular biologist for testing purpose has drawn attention as they fully ignored biotechnologist. BABG gave a press release by expressing its concern in the recruitment criteria regarding COVID-19 testing facility establishment. This press release was published in many national dailies and also created a noise in social network among biotech graduates. BABG team further met with the directorate general of Health Services authority and expressed the situation faced by our graduates as well as discrimination in recruitment process.
Efforts paid by biotech graduates since March should not go in vain. The DGHS authorities recently issued a letter of recognition to support the voluntary works of biotechnologists and include biotechnology degree as eligibility criteria in a recent temporary recruitment circular for COVID-19 laboratory consultant in Bhola. We are thankful to DGHS, health ministry as well as to authorities who are involved in COVID-19 management but our work is not done yet. It is good that our volunteers works are at least recognised but with this recognition now they should be given equal opportunities to compete and considered in all molecular and medical diagnostics expert position.
As I said earlier, the government alone is not enough to fight this war, BABG wants to provide full support to government in COVID-19 management. UNFPA is working with IEDCR to increase the number of testing throughout the country. BABG had a talk with UNFPA to provide skilled biotechnologist so that testing capacity can be increased.
On the one side, BABG members have to raise their voices to draw attention of authorities so that the authorities can realise that we have enough skilled human resources. And on the other side, BABG has to enlist more volunteers and experts to prepare them to response anytime when they are needed.
University professors from biotechnology departments and BABG executive committee members are writing and talking in both print and electronic media in order to establish the equal right for biotechnologists. BABG already had a discussion with all public university biotechnology department chairman and director general of national institute of biotechnology Md Salimullah.
In that discussion, all agreed that absence of national biotechnology policy is the main reason why biotechnologists are not yet recognised and properly utilised for service. NIB already prepared and submitted a draft of national biotechnology policy but unfortunately due to COVID-19 crisis that policy is yet to be finalised. But, till national biotechnology policy is available, we cannot wait while our graduates are very much capable of doing the test. Moreover, they have the knowledge about how this technology works. Therefore, they involved themselves since the beginning of this crisis. With proper opportunity as well as benefits, we could use more skilled human resources. Besides encouraging and promoting these graduates, BABG is also focusing on developing more skilled volunteers for future. BABG is already planning on-line based training for all biotechnology graduates which will be available across the country.
June 25, 2020 was the 25th anniversary of biotechnology in Bangladesh. This is heart breaking fact that still biotechnologist are not equally treated with other biological graduates for service.
In this COVID-19 situation, now our focus should be how we can engage more of these skilled biotechnologists. We can introduce shifting system in laboratories so that by using the same facility we can increase number of tests. This will involve engagement of few more skilled persons but will not increase extra logistical cost for existing facility.
We should recognise that those biotechnologists who worked in many COVID-19 laboratories are also our frontline fighters like many others in this crisis. If we want to increase our capability we have to promote them as well as engage many more frontline fighters to win against COVID-19.
Mahmud-Al-Rafat is the communication and publication secretary of Bangladesh Association of Biotechnology Graduates
View original post here:
Biotechnologists: the unsung heroes of COVID-19 war in Bangladesh - newagebd.net
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022